-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Savara (SVRA), Highlights Molbreevi Potential
-
-
-
-
-
-
-
FDA files Savara's MOLBREEVI application for rare lung disease
-
-
-
-
-
-
-
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
-
15,931 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


